Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | The current treatment landscape for SCD

Robert Clark Brown • 10 Jun 2021
EHA 2021
Non-Malignant Sickle Cell Disease Antibodies Crizanlizumab FT-4202 Hydroxyurea L-glutamine Voxelotor

Robert Clark Brown, MD, PhD, Children’s Healthcare of Atlanta, Atlanta, GA, gives an overview of the current treatment landscape for sickle cell disease (SCD), highlighting the use of hydroxyurea and the use of more recently approved therapies including voxelotor, L-glutamine and crizanlizumab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Robert Clark Brown, MD, PhD, has participated in consultancy work with Global Blood Therapeutics, Imara and Novo Nordisk; and has received research support from Forma Therapeutics, Global Blood Therapeutics, Imara and Novartis.

More from Robert Clark Brown

2:56
Psychometric properties of a daily diary for patients with SCD
Robert Clark Brown • 10 Jun 2021
1:15
The safety and efficacy of voxelotor in pediatric patients with SCD
Robert Clark Brown • 10 Jun 2021
2:12
Alternative clinical outcomes for patients receiving voxelotor for SCD
Robert Clark Brown • 10 Jun 2021
3:05
Updates on the Phase I study of FT-4202 for SCD
Robert Clark Brown • 10 Jun 2021

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals